Even though the onset of AIHA has been occasionally reported under ibrutinib, possibly reflecting inadequate disease control, our case clearly indicate that ibrutinib is a valuable therapeutic option for steroid-resistant AIHA occurring during the natural history of CLL.
Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion
Quaglia, Francesca Maria;
2016-01-01
Abstract
Even though the onset of AIHA has been occasionally reported under ibrutinib, possibly reflecting inadequate disease control, our case clearly indicate that ibrutinib is a valuable therapeutic option for steroid-resistant AIHA occurring during the natural history of CLL.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
